Skip to main content

Table 4 Correlation between NuclErbB-2 and MembErbB-2 expression studied by immunofluorescence with C-18 antibody

From: Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer

  MembErbB-2, n (%) Total N (%) P value
  Negative Positive   
NuclErbB-2 expression in the 226 patient cohort     
   Negative (0/1+) 126 (55.7)a 24 (10.6) 150 (66.4) 0.265b
   Positive (2+/3+) 68 (30.0) 8 (3.7) 76 (33.6)  
   Total N (%) 194 (85.8) 32 (14.2) 226 (100)  
   Negative (0) 87 (38.5) 19 (8.4) 106 (46.9) 0.127
   Positive (1+/2+/3+) 107 (47.4) 13 (5.7) 120 (53.1)  
   Total N (%) 194 (85.8) 32 (14.2) 226 (100)  
NuclErbB-2 expression in the 298 patient cohort c     
   Negative (0/1+) 171 (57.5) 30 (10.0) 201 (67.4) 0.176
   Positive (2+/3+) 88 (29.5) 9 (3.0) 97 (32.6)  
   Total N (%) 259 (86.9) 39 (13.1) 298 (100)  
  1. a Percentage of the total cohort. b Correlation between NuclErbB-2 and MembErbB-2 expression was determined by χ2 test. c We added to our original cohort 73 patients whose NuclErbB-2 and MembErbB-2 status by immunofluorescence staining we knew, but had not been included in our complete study because we lacked information regarding several clinicopathologic characteristics